An observational study in Head & Neck Cancer, sponsored by Istituto Clinico Humanitas. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Istituto Clinico Humanitas · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Head and Neck Neoplasms with a site in Italy — 43 open to participants now, 57 under way, 6 of them phase 3. Head and Neck Neoplasms · Italy.
Among the 134 studies in Head and Neck Neoplasms with a site in Italy, this one is the 30th largest by planned enrollment of the 37 observational ones that give a count, is one of 5 that started in 2026, is one of 37 observational ones, reaches primary completion later than 53 of the 56 other live ones, and was the 132nd registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →43 of the 134 studies in Head and Neck Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
University of Pavia · Sites in Italy
Ages 18+
University of Turin, Italy · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18–99
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 44 · Phase 3 29
First in 1992; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 100 across 505 observational studies indexed under Head and Neck Neoplasms.
Median enrollment 160 across the 97 interventional studies, 200 across the 37 observational. Of the 64 that completed or were terminated, 28 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 134 have an industry lead sponsor. The 10 most frequent:
Istituto Clinico Humanitas is the lead sponsor of 280 studies on the registry; 70 are open to participants now.
Istituto Clinico Humanitas has 2 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Head and Neck Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07491536University of PaviaOzone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis | 2026-12-01 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT06809673Ospedale Policlinico San MartinoPA.RI.GE. Study. The Prognostic Role of Inflammatory Circulating Biomarkers in HNSCC: a Prospective Multicentric Trial | 2026-12-31 |
| NCT07508319European Institute of OncologyRole of the Immune System in Preventing Laryngeal Cancer | 2026-12-31 |
| NCT06344208European Institute of OncologyPredicting Toxicity in Elderly Patients With Head and Neck Cancer | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 134 studies in Head and Neck Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Some patients with head and neck cancer may develop a tumor recurrence in an area that has already been treated with radiotherapy. In these situations, surgery is not always possible, and giving radiotherapy again can be challenging because nearby healthy tissues and organs may already have received high radiation doses.
The REPROton-HN study is evaluating the use of proton therapy for these patients. Proton therapy is a type of radiation treatment that can deliver radiation more precisely to the tumor while reducing exposure to surrounding healthy tissues.
The aim of the study is to better understand how safe and effective proton therapy is when used as a second course of radiation treatment. Researchers will monitor side effects, tumor control, survival, and patients' quality of life. The results may help improve treatment planning and identify which patients are most likely to benefit from proton therapy in the future.
All patients with head and neck cancer who develop locoregional recurrence after prior radiotherapy and candidate to re-irradiation with proton therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
treatment of recurrence of tumor with protontherapy
Evaluation of toxicities profiles
To Evaluate Short and Long-Term Toxicity Profiles - Assess acute and late-onset side effects and compare toxicity rates with conventional radiotherapy. Adverse event will be evaluated through CTCAE V.5.0 classification
Time frame: from enrollment to 5 years follow up
Number of partecipants with disease free survival
assessment of the number of patients with no disease progression at follow-ups. Assessed by conventional imaging (PET, RMI, CT)
Time frame: from enrollment to 5 years follow up
number of patients with Loco-regional control
assessment of the number of patients with no loco-regional disease progression at follow-ups. Assessed by conventional imaging (PET, RMI, CT)
Time frame: from enrollment to 5 years follow up
number of patient with distant metastasis free survival
Assessment of the number of patients with no distant metastasis at follow-ups. Assessed by conventional imaging (PET, RMI, CT)
Time frame: from enrollment to 5 years follow up
Quality of life outcomes
evaluation of quality of life of patients through the completion of questionnarie QLQ-C30. Question with a scale from 1 to 4 (1 low quality of life - 4 high quality of life)
Time frame: from enrollment to 5 years follow up
assessment of treatment response
assessment of the pathology's response to treatment by imaging
Time frame: from enrollment to 5 years follow up
Started May 2026 (actual). Primary completion is estimated for Jun 2031, 61 months after the start.
Of 215 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 144. This study's planned 61 months is below that.
Counting every sponsor, half of 237 studies reached it within 71 months; a quarter within 29 and three quarters within 144.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.